ZYBT vs ATXG

For growth investors, Zhengye Biotechnology Holding Limited (ZYBT) is the stronger pick with -12.

0% revenue growth year-over-year, versus -18. 9% for Addentax Group Corp. (ATXG). The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Zhengye Biotechnology Holding Limited (ZYBT) delivered a total return of -79.

9%, compared to -99. 6% for Addentax Group Corp. (ATXG). Over 10 years, the gap is even starker: ZYBT returned -79. 9% versus ATXG's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Addentax Group Corp.

(ATXG) is the lower-risk stock at 1. 44β versus Zhengye Biotechnology Holding Limited's 1. 87β — meaning ZYBT is approximately 30% more volatile than ATXG relative to the S&P 500. On balance sheet safety, Zhengye Biotechnology Holding Limited (ZYBT) carries a lower debt/equity ratio of 25% versus 103% for Addentax Group Corp. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Zhengye Biotechnology Holding Limited (ZYBT) is pulling ahead at -12.

0% versus -18. 9% for Addentax Group Corp. (ATXG). Over a 3-year CAGR, ZYBT leads at -4. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Zhengye Biotechnology Holding Limited (ZYBT) is the more profitable company, earning 6.

1% net margin versus -121. 8% for Addentax Group Corp. — meaning it keeps 6. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ZYBT leads at 8. 8% versus -43. 5% for ATXG. At the gross margin level — before operating expenses — ZYBT leads at 49. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, ZYBT (5.

3% yield) pays a dividend. ATXG does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Zhengye Biotechnology Holding Limited (ZYBT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (5.

3% yield). Both have compounded well over 10 years (ZYBT: -79. 9%, ATXG: -99. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ZYBT (Healthcare) and ATXG (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ZYBT is a small-cap income-oriented stock; ATXG is a small-cap quality compounder stock. ZYBT pays a dividend while ATXG does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.